The approval is based on the phase 3 FIDELIO-DKD trial, in which Kerendia (finerenone) reduced the risk of kidney disease progression or renal death by 18% when added to the highest tolerated dose ...
NEW YORK, Jan. 7 /PRNewswire-FirstCall/ -- Fidelio Acquisition Company, LLC, whose members are Sony Corporation of America, a subsidiary of Sony Corporation, Royal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback